Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

A -- SN06-27

Active
SN06-27Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The contract pertains to a special notice issued by the Defense Advanced Research Projects Agency (DARPA) under the Defense Sciences Office (DSO) for the Accelerated Manufacturing of Pharmaceuticals (AMP) program. The program aims to develop a highly efficient and flexible manufacturing system capable of producing three million doses of Good Manufacturing Practice (GMP) quality vaccines or monoclonal antibodies within a 12-week timeframe. The initiative emphasizes the formation of integrated, multidisciplinary teams with the expertise and facilities necessary to meet the program’s objectives and milestones. The notice includes a web chat held on May 31, 2006, designed to facilitate collaboration among prospective research organizations and provide answers to frequently asked questions regarding the Broad Agency Announcement (BAA) associated with the AMP program. Participation in the web chat required online registration through the designated teaming website, where potential collaborators were also encouraged to showcase their technological capabilities to promote teaming. No fees were associated with participation in the information session or teaming activities. Further technical inquiries could be directed to the program manager, Dr. Michael Callahan, while webmaster assistance was available through a specified contact. This announcement is not a solicitation for proposals, but serves to encourage formation of capable teams and provide preliminary information ahead of the official solicitation, which can be accessed through the DARPA BAA website. The contracting office is located in Arlington, Virginia, under the Department of Defense.

General Info

DARPA seeks teams to develop rapid manufacturing system for 3 million GMP vaccine doses in 12 weeks.

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

VA

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

Posted

special-notice

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Defense Advanced Research Projects Agcy
Contacts1 person available
OfficeARLINGTON, VA, 222032114, USA
Office AddressARLINGTON, VA, 222032114, USA
Contacts
Michael G CallahanDSO Program Manager

Full Description

Show more
Special Notice 06-27: Accelerated Manufacturing of Pharmaceuticals Web Chat DATE: May 31, 2006 TECHNICAL POC: Dr. Michael Callahan, DARPA/DSO, Ph: (571) 218-4537, URL: http://www.sainc.com/ampteaming/ Accelerated Manufacturing of Pharmaceuticals (AMP), SN 06-27. The Defense Sciences Office (DSO) of the Defense Advanced Research Projects Agency (DARPA) is sponsoring a web chat for AMP, a new DARPA program. The vision of the Accelerated Manufacturing of Pharmaceuticals (AMP) program is to create an extremely rapid, flexible and cost-effective manufacturing system capable of producing three million doses of GMP-quality vaccines or monoclonal antibodies (mAB) within 12 weeks. A highly integrated, multi-disciplinary team capable of fulfilling the entire vision, meeting all program objectives and milestones for each phase of the program is strongly encouraged. The web chat session will be held on the teaming website http://www.sainc.com/ampteaming/ on May 31, 2006 from 1400 to 1600 EST. The goals of the web chat session are (a) to encourage and promote teaming arrangements among potential research organizations that have the relevant expertise, facilities, and capabilities for executing a research and development program responsive to the AMP program goals and (b) to answer FAQ regarding the AMP BAA. There is no fee for any teaming and information session activities. Online registration on the teaming site is required to participate in the web chat. In addition, teams are encouraged to post their general technology capabilities on the teaming website to encourage teaming. Additional information regarding the web chat can be found on the AMP Teaming website http://www.sainc.com/ampteaming/ . Webmaster questions should be directed to Chris Schrader schrac@sainc.com. Additional technical information can be obtained from Michael Callahan (michael.callahan@darpa.mil). Please refer to the - AMP Web Chat Teaming & Information Session in correspondence. This announcement is not a request for proposals. The solicitation document is available at http://www.darpa.mil/baa/baa06-31.html. Original Point of Contact Michael Callahan, DARPA Program Manager, Phone (571) 218-4537 Teaming Website: http://www.sainc.com/ampteaming/.

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Federal
Pre-Award Synopsis Texas Shield
Solicitation # DARPA-SN-27-07
The Defense Advanced Research Projects Agency (DARPA), through its Biological Technologies Office (BTO), intends to enter into an agreement with The University of Texas System consortium of universities for the Texas Shield Program. This integrated research initiative, identified by solicitation number DARPA-SN-27-07 and NAICS code 541714, focuses on developing autonomous and semi-autonomous medical technologies and scalable solutions for critical medical consumables. The primary goal is to support lifesaving medical care in contested, austere, and resource-limited environments. Key technical areas of focus include autonomous medical and robotic surgical systems, casualty evacuation, artificial-blood and supply innovation, AI-enabled clinical decision support, and mass-casualty science and simulation. This notice is a pre-award synopsis and is not a request for proposals or a competitive solicitation. Interested entities are invited to submit information by November 15, 2026, to TexasShieldxBTO@darpa.mil detailing their technical expertise, integrated research infrastructure, clinical-validation capabilities, and multi-institutional coordination capacity. Additionally, respondents must describe their consortium organizational structure, commercialization capabilities, facility clearance levels, and their ability to handle Controlled Unclassified Information. The government will not reimburse any costs associated with the preparation or submission of information in response to this notice.
Defense Advanced Research Projects Agcy

POSTED

4 days ago

DEADLINE

in 26 days
View Details
NAICS: 541714
New
Federal
Q--AMPLICON SEQUENCING SERVICES
Solicitation # 140G0226Q0047
Solicitation 140G0226Q0047 is a firm-fixed-price request for a Blanket Purchase Agreement (BPA) to provide next generation amplicon sequencing services for the USGS Upper Midwest Water Science Center’s Michigan Bacteriological Research Laboratory. The scope of work includes providing all equipment, labor, travel, and materials necessary to support research on bacterial pathogens, harmful algal blooms, microbial ecology, antibiotic resistance, and microbial source tracking. Key technical requirements include the use of Illumina MiSeq or AVITI sequencing technologies and the potential for library preparation for 16S V4 amplicon sequencing. The BPA has a total not-to-exceed value of 250,000 dollars with an estimated period of performance from September 17, 2026, to September 16, 2031. The award process prioritizes non-priced factors significantly over cost, focusing on the offeror's qualifications and technical performance. Evaluation criteria include a detailed listing of on-site equipment and calibration dates, personnel experience, internal quality assurance procedures, and a technical narrative not exceeding two pages. Performance will be executed in Lansing, Michigan, with delivery terms set as FOB Destination. Administrative requirements include electronic invoicing via the Internet Payment Platform and compliance with various federal regulations, including the Buy American Act and specific security prohibitions regarding telecommunications equipment. Proposals must be submitted to the USGS OAG Denver Acquisition Branch by September 11, 2026.
Ofc Of Acquisition Grants-Denver

POSTED

4 days ago

DEADLINE

in 3 days
View Details

More opportunities from Department Of Defense → Defense Advanced Research Projects Agcy

Same awarding agency

NAICS: 541715
New
Federal
Intrinsic Market Resilience (IMR)
Solicitation # DARPA-PS-26-138
The Intrinsic Market Resilience (IMR) program, solicited by the DARPA Information Processing Techniques Office under DARPA-PS-26-138, is a 32-month initiative spanning Fiscal Years 2027 through 2029. The program aims to protect essential U.S. economic sectors from systemic risks and adversarial attacks targeting the public interfaces of modern electronic markets. By combining Large Language Model (LLM) automation with rigorous mathematical modeling, IMR seeks to develop tools that automatically translate informal regulatory and technical specifications into formal models to identify hidden weaknesses and recommend structural repairs. The work is divided into three technical areas: TA1 focuses on modeling and analysis, TA2 on resiliency and repair, and TA3 on establishing test and evaluation frameworks to validate the outputs of the first two areas. This procurement is conducted as an Other Transaction (OT) for Prototype Agreement under 10 U.S.C. 4022, with anticipated award ranges of 4.5 to 5 million dollars for TA1, 2.5 to 3 million dollars for TA2, and 5 to 6.5 million dollars for TA3. Eligible participants include small businesses, nonprofit research institutions, and nontraditional defense contractors. Proposers must adhere to strict security requirements, including CMMC Level 1 compliance at award and CMMC Level 2 status or a detailed compliance plan. All information must be handled according to NIST 800-171 and DFARS 252.204-7012 standards. Evaluation is based on technical approach, qualifications, technology transition viability, price, and security, with a particular emphasis on innovation and the feasibility of the proposed technical solution.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

4 days ago

DEADLINE

in about 2 months
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS